Observations on spontaneous tumor formation in mice overexpressing mitotic kinesin Kif14

• Main Authors: Kamakshi Sishtla, Natalie Pitt, Mehdi Shadmand, Michael N. O’Hare, Rania S. Sulaiman, Anthony L. Sinn, Keith Condon, Karen E. Pollok, George E. Sandusky, Timothy W. Corson
• Format: Article
• Language: English
• Published: Nature Publishing Group 2018-11-01
• Series: Scientific Reports
• Subjects: Mitotic Kinesin; Fatal Lymphoma; KIF Expression; Protein Regulator Of Cytokinesis 1 (PRC1); Citron Kinase
• Online Access: https://doi.org/10.1038/s41598-018-34603-4

Abstract The KIF14 locus is gained and overexpressed in various malignancies, with prognostic relevance. Its protein product, a mitotic kinesin, accelerates growth of normal mammary epithelial cells in vitro and retinoblastoma tumours in a mouse model, while KIF14 knockdown blocks growth of brain, liver, ovarian, breast, prostate, and other tumour cells and xenografts. However, the tumour-initiating effects of Kif14 overexpression have not been studied. We aged a cohort of Kif14-overexpressing transgenic mice and wild-type littermates and documented survival, cause of death, and tumour burden. The Kif14 transgene was expressed in all tissues examined, and was associated with increased proliferation marker expression. Neither mouse weights nor overall survival differed between genotypes. However, Kif14 transgenic mice showed a higher incidence of fatal lymphomas (73 vs. 50%, p = 0.03, Fisher’s exact test), primarily follicular and diffuse B-cell lymphomas. Non-tumour findings included a bilateral ballooning degeneration of lens in 12% of Kif14 transgenic mice but no wild-type mice (p = 0.02). Overall, this work reveals a novel association of Kif14 overexpression with lymphoma but suggests that Kif14 does not have as prominent a role in initiating cancer in other cell types as it does in accelerating tumour development in response to other oncogenic insults.